Introduction: Imnnunotherapy has become a promising approach for the treatment of NSCLC. In order to stimulate the host immune system against tumour antigens, several cancer vaccines have been generated and evaluated. Belagenpumatucel-L is a whole tumour cell vaccine expressing the antisense strand of the TGF-beta 2 gene.Areas covered: The purpose of this article is to review the most relevant findings of clinical trials testing belagenpumatucel-L in advanced NSCLC patients.Expert opinion: Although the Phase III trial investigating belagenpumatucel-L in stage III/IV patients did not meet its primary end point, a survival benefit was observed in several subgroups of patients. Further studies are needed in order to select patients who may benefit from this vaccine.

Belagenpumatucel-L for the treatment of non-small cell lung cancer

Grossi, Francesco
2015-01-01

Abstract

Introduction: Imnnunotherapy has become a promising approach for the treatment of NSCLC. In order to stimulate the host immune system against tumour antigens, several cancer vaccines have been generated and evaluated. Belagenpumatucel-L is a whole tumour cell vaccine expressing the antisense strand of the TGF-beta 2 gene.Areas covered: The purpose of this article is to review the most relevant findings of clinical trials testing belagenpumatucel-L in advanced NSCLC patients.Expert opinion: Although the Phase III trial investigating belagenpumatucel-L in stage III/IV patients did not meet its primary end point, a survival benefit was observed in several subgroups of patients. Further studies are needed in order to select patients who may benefit from this vaccine.
2015
2015
Belagenpumatucel-L; NSCLC; TGF-β2; vaccines; Antigens, Neoplasm; Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Immunotherapy; Lung Neoplasms; Transforming Growth Factor beta2
Rijavec, Erika; Biello, Federica; Genova, Carlo; Barletta, Giulia; Maggioni, Claudia; Dal Bello, Maria Giovanna; Coco, Simona; Truini, Anna; Vanni, Ir...espandi
File in questo prodotto:
File Dimensione Formato  
Rijavec E - Expert Opin Biol Ther 2015.pdf

non disponibili

Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 560.83 kB
Formato Adobe PDF
560.83 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11383/2142651
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 12
social impact